Commissioner Crawford Hosts Speak Up Texas Event San Antonio April 17

TDI Commissioner Amanda Crawford will host a Speak Up, Texas! community event on Friday, April 17, 2026, from 5 to 6:30 p.m. at UT San Antonio's Downtown Campus in the Durango Building's Riverwalk Room B (501 W. Cesar E. Chavez Blvd.). The event invites Texans to share ideas on strengthening and improving the home and auto insurance market, learn tips for shopping for insurance, and understand how TDI can assist Texas consumers. Texans unable to attend in person can submit feedback online at tdi.texas.gov/speakuptexas.

Leonardo Villar Presents BanRep Board Report to Senate

Leonardo Villar, Gerente General del Banco de la República, presentó el Informe de la Junta Directiva del Banco al Congreso de la República ante la Comisión Tercera del Senado el miércoles 22 de abril de 2026. La presentación se realizó como parte de las funciones de rendición de cuentas del banco central ante el legislativo colombiano. El documento incluye la intervención de Villar Gómez ante los senadores de la comisión.

Bank Co-Directors Discuss Monetary Policy Book at Bogotá Book Fair 2026

Banco de la República de Colombia announces its participation in the 2026 International Book Fair of Bogotá (FILBo), where co-directors Bibiana Taboada and Mauricio Villamizar will host a public conversation on April 23 at 2:00 p.m. in Auditorium Pabellón Colombia about their book 'Mitos y realidades de la política monetaria'. The event is open to the general public and aims to promote informed debate about monetary policy, covering topics such as inflation, interest rates, labor markets, production, exchange rates, climate change, inequality, and public policy.

Alerta: Usan IA para Suplantar al Gerente General del BanRep en Videos Falsos

El Banco de la República emitió una alerta pública el 18 de abril de 2026 desmentiendo un video falso publicado en redes sociales que utiliza inteligencia artificial para manipular la imagen del Gerente General, simulando una entrevista en Noticias RCN. La entidad aclaró que los contenidos son fraudulentos y no corresponden a comunicaciones oficiales. Como medida de precaución, el Banco recomienda a la ciudadanía verificar siempre la fuente de la información, no diligenciar datos personales en enlaces no confiables y consultar únicamente los canales oficiales del Banco para información verificada.

H.R. 4690 Motion to Recommit Fails 203-214

The House of Representatives voted on H.R. 4690 (Reliable Federal Infrastructure Act), with a motion to recommit failing 203-214. All Republicans voted against recommitment while all Democrats plus one Independent voted in favor. The vote took place on April 22, 2026 during the 119th Congress, 2nd Session.

H.R. 6387 FIRE Act Passes House 220-198

The House of Representatives passed H.R. 6387, the FIRE Act, by a vote of 220-198 on April 22, 2026. Republicans supported the bill 211-1 while Democrats opposed it 197-8 with 12 members not voting. The bill now proceeds to the Senate for consideration before it can be presented to the President for signature.

H.R. 4690 Reliable Federal Infrastructure Act Passed 215-202

The House passed H.R. 4690, the Reliable Federal Infrastructure Act, by a vote of 215-202 on April 22, 2026 during the 119th Congress, 2nd Session. The vote split largely along party lines with 209 Republicans and 6 out of 218 Democrats supporting passage, while 1 Republican voted against. The bill now proceeds to the Senate for consideration.

FIRE Act Motion to Recommit Fails 206-214

The U.S. House of Representatives voted on a Motion to Recommit regarding the FIRE Act on April 22, 2026. The motion failed with 206 votes in favor and 214 votes against, with 10 members not voting and 0 present. Republicans voted uniformly against the motion (213 nay, 4 not voting) while all Democrats voting (206) supported it.

Rural Support Resolution Passes 220-196

H. Res. 1182, expressing support for rural communities as environmental stewards, energy resource suppliers, food production providers, and drivers of economic stability, passed the House on April 22, 2026 by a vote of 220-196. The resolution passed largely along party lines with 212 Republicans and 7 Democrats voting in favor, while 196 Democrats voted against. As a simple House resolution, this measure carries no binding legal effect and serves as an expression of congressional sentiment.

H. Res. 1189 Previous Question Vote Passes 180-179

The House voted 180-179 on April 22, 2026 to order the Previous Question on H. Res. 1189, a rule providing for floor consideration of H.R. 4690, H. Res. 1182, H.R. 1897, and H.R. 5587. The margin was razor-thin with 72 members not voting. Republicans voted uniformly in favor (179-0) while all 179 present Democrats voted against, with one Independent joining Republicans.

House Passes H. Res. 1189, 211-206

The House passed H. Res. 1189 by a vote of 211 to 206 on April 22, 2026. The procedural resolution provides for floor consideration of H.R. 4690, H. Res. 1182, H.R. 1897, and H.R. 5587, governing debate time allocation and permissible amendments for each measure. The vote split sharply along party lines with all 205 voting Democrats opposed, 210 of 211 Republicans in favor, one Independent voting yes, and 14 members not voting.

RBZ Graduate Trainee Programme 2026-2028 Law Media Studies

The Reserve Bank of Zimbabwe (RBZ) has announced a 2-year Graduate Trainee Programme for the 2026-2028 cohort, inviting applications from graduates holding a minimum First Class (1) Degree in Law or Media Studies. The programme offers structured training in central banking operations including monetary policy, financial markets, banking supervision, and economic research. Interested candidates should submit applications with CV, certified copies of educational certificates, ID and transcript to gtcareers@rbz.co.zw.

ZiG Stability, 4.1% Inflation, US$1.4B Reserves, New Banknotes

The Reserve Bank of Zimbabwe published its Q1 2026 quarterly snapshot reporting macroeconomic and financial sector developments. Key indicators include single-digit annual ZiG inflation of 4.1% achieved in January 2026 for the first time in over three decades, sustained month-on-month inflation averaging 0.2% through March 2026, and foreign currency reserves standing at US$1.4 billion representing approximately 1.5 months of import cover as of 31 March 2026. Foreign currency receipts totaled US$4.97 billion in the first three months of 2026, a 54.1% increase compared to US$3.22 billion in the same period of 2025, while the interbank exchange rate remained stable at approximately ZiG25 per US dollar. The Reserve Bank also launched the upgraded BiG 5 ZiG Banknote Series alongside a nationwide education and awareness campaign.

Diogo Thomson Named Interim CADE President

Conselheiro Diogo Thomson de Andrade assumed interim presidency of Brazil's Conselho Administrativo de Defesa Econômica (CADE) on April 12, 2026, succeeding Gustavo Augusto whose term ended. Thomson has been with CADE since 2007, serving as a prosecutor, administrative instructor, and deputy superintendent for over a decade before joining the Tribunal as a counselor in 2023. His appointment crowns a near-two-decade career traversing every level of Brazil's competition authority.

CADE Publishes 2025 Integrated Management Report

CADE Brazil published its 2025 Integrated Management Report on April 15, 2026, consolidating institutional results, governance practices, and public resource management under four structural axes: organizational overview, governance and strategy, risk management, and budget execution. The report reflects the agency's work in promoting fair and efficient competition aligned with constitutional principles.

Three Cases on CADE Agenda Thursday Diogo Thomson

CADE Brazil published the agenda for its 264th Ordinary Judgment Session in the Diário Oficial da União on April 16, 2026. The session is scheduled for Thursday April 23 at 10h, broadcast live on YouTube, and will be the first presided over by interim president Diogo Thomson who took office on April 12. Three cases are listed: Administrative Inquiry 08700.003498/2019-03 against Google Inc. and Google Brasil Internet Ltda. (relator Gustavo Augusto, vote-vista Camila Cabral); Administrative Proceeding 08700.002545/2023-70 from the Paraná state prosecutor against six respondents including Augustinho Stang and several fuel and commerce companies (relator José Levi); and Administrative Proceeding 08700.002556/2026-01 for incidental procedural sanctions against WhatsApp LLC and Facebook Serviços Online do Brasil (relator Carlos Jacques).

Illinois State Fair 2026, 100 Days Celebration, May 5th

The Illinois Department of Agriculture announced the 2026 Illinois State Fair "100 Days Out" Celebration, scheduled for May 5, 2026 from 10:30 a.m. to 2:30 p.m. at the Reisch Pavilion on the Illinois State Fairgrounds. The free event will feature food vendors including Mickey's Massive Burritos, On Point Concessions, Taft's Mr. Ribeye, Vose's Korndog, and Scoop Du Jour, along with prize package giveaways. The 2026 Illinois State Fair itself will run from August 13-23.

11 Therapy Canine Teams Graduate in Illinois Crisis Response Program

The Illinois Law Enforcement Training and Standards Board (ILETSB), in partnership with the Cook County Sheriff's Office (CCSO), graduated the inaugural cohort of the nation's first Crisis Response Therapy Canine Certification Program on April 22, 2026. The 11 certified therapy canine teams representing seven Illinois agencies completed rigorous training in crisis intervention, behavioral health awareness, and canine-handler coordination. The program establishes standardized training guidelines for therapy canines working alongside law enforcement in mental health calls, community engagement, and post-trauma response situations.

Illinois Green Film Tax Credit, 5% Additional Uplift

Illinois has launched a first-in-the-nation Green Film Tax Credit program offering an additional 5% tax credit uplift for film and television productions that achieve "certified green production" status through the Illinois Film Office, which uses a comprehensive scoring system to measure environmental impact across all phases of production. The announcement coincides with Illinois' film production expenditures reaching a record $703 million in 2025, supporting approximately 18,000 industry hires. The program is designed to incentivize sustainable practices including waste minimization, energy reduction, efficient transportation, sustainable materials, and responsible food practices on set.

Toyota ShareLunker Program 2026 Season Delivers 18 Legacy Class Fish From 10 Texas Lakes

The Texas Parks and Wildlife Department announced results of the 2026 Toyota ShareLunker collection season, celebrating the program's 40th anniversary with 18 Legacy Class ShareLunkers submitted from 10 different public lakes across Texas. Two waterbodies (Hords Creek Reservoir and Ellison Creek Reservoir) recorded their first Legacy Class fish, while four lakes set new waterbody records. O.H. Ivie retained bragging rights for most entries for the sixth consecutive season with five Legacy Class ShareLunkers, bringing its total to 63 since 2020. The program focuses on habitat improvement, stocking programs, and genetic research for largemouth bass conservation.

Governor Spanberger Signs Momnibus Bills to Improve Maternal Healthcare, Support Virginia Mothers

Governor Abigail Spanberger signed the Virginia Momnibus legislative package on April 22, 2026, enacting four bipartisan bills to improve maternal healthcare coverage. The package includes HB1400 expanding maternal mental healthcare screenings, HB1403 directing the Department of Health to develop a Severe Maternal Morbidity reporting system, HB425 authorizing Medicaid reimbursements for remote monitoring of high-risk pregnant women, and HB1353 directing the Commissioner of Health to assess a statewide maternal health safety initiative. The legislation targets Virginia's high maternal mortality rate, particularly for Black women who face elevated risks compared to other demographics.

Governor Spanberger Statement on Redistricting Referendum Outcome

Governor Abigail Spanberger released a statement on April 21, 2026, following Virginia voters' approval of a temporary redistricting measure. The approved measure was designed to push back against claims of entitlement to additional Republican seats in Congress. The statement acknowledges voter rejection of similar demands in other states and reaffirms commitment to Virginia's bipartisan redistricting commission resuming work after the 2030 census.

Additional Practical Exam Testing Date April 29, Montgomery

PSI, the Alabama Board of Cosmetology and Barbering testing partner, has added an additional practical exam testing date on April 29 in Montgomery, Alabama. This supplementary testing event precedes the launch of updated cosmetology and barbering examinations scheduled for May 1, 2026. Test takers are instructed to log into their PSI online portal, select Montgomery Practical as the site location, and schedule their exam before all available spots are filled.

Parole Hearing Outcomes Week of April 13-17, 2026

The California Board of Parole Hearings published outcomes for approximately 90 parole suitability hearings conducted during the week of April 13 through April 17, 2026, spanning multiple counties including Los Angeles, Riverside, San Bernardino, and others. Outcomes include Waive (1-3 year), Deny (3-5 year), Grant (under PC 3041.1 or PC 3041.2), Postpone (0-6 month), Stipulate (3 year), and one Rescission. These records reflect individual parole hearing determinations and do not create new compliance obligations for the public.

Health and Wellness Coaching for Thyroid Cancer Survivors, NCT07545837

Clinical trial NCT07545837 registered on ClinicalTrials.gov evaluates a patient-centered health and wellness coaching (HWC) intervention targeting adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid cancer. The trial will enroll thyroid cancer survivors who have undergone surgery, radioactive iodine, and/or lifelong levothyroxine therapy with regular thyroid stimulating hormone monitoring. Interventions include counseling, interviews, and questionnaire administration to assess HWC's impact on self-care, health-related goal-setting, and survivorship care outcomes.

Phase 1 CAR T Cell Trial for Recurrent High-Grade Gliomas

This Phase 1 clinical trial registered on ClinicalTrials.gov (NCT07544992) will evaluate the safety and optimal dosing of EGFR/IL13Rα2 pool-CAR T cells administered locoregionally (via intracranial catheter) in patients with recurrent or progressive high-grade gliomas, including recurrent astrocytoma (IDH-mutant, grade 4) and recurrent glioblastoma (IDH-wildtype). The trial involves leukapheresis to collect patient T cells, genetic engineering to express chimeric antigen receptors targeting EGFR and IL13Rα2 proteins on tumor cells, and subsequent infusion of the modified cells.

Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes

This clinical trial registration (NCT07546409) describes a randomized study assessing whether older adults with prediabetes show differences in brain glucose uptake and cognitive processing speed compared to age-matched controls with normal glucose levels. The trial will test a single dose of an exogenous ketone monoester supplement (DeltaG) against placebo in approximately 100 participants, measuring outcomes via 18F-FDG-PET/MRI brain imaging and cognitive testing. Estimated study completion date is April 22, 2026.

Ultrasound-guided Pharmacopuncture Spinal Disease Registry Trial, 600 Patients, 6 Sites

The NIH ClinicalTrials.gov registry has posted an observational multi-center registry study (NCT07543692) evaluating the safety and effectiveness of ultrasound-guided pharmacopuncture for patients with spinal diseases. The study will enroll 600 patients aged 19 to under 70 across six Korean medicine hospitals, requiring a pain Numeric Rating Scale score of 5 or higher for eligibility. Participants already planned to receive ultrasound-guided pharmacopuncture as part of routine clinical care will be observed; the primary outcome is change in most dominant spinal pain intensity from baseline to 4 weeks. Secondary outcomes include functional disability (NDI/ODI), quality of life (EQ-5D-5L), and patient satisfaction, with safety monitored via adverse event assessment at every visit. This is a non-interventional registry study with no new compliance obligations for external parties.

Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus

A new observational study (NCT07545408) registered on ClinicalTrials.gov will evaluate subclinical atherosclerosis in children and adolescents with juvenile systemic lupus erythematosus (SLE) by measuring carotid intima-media thickness (CIMT), and will assess associations with both traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration). The study is listed as observational with an anticipated end date.

RAB001 Phase 1, Osteonecrosis, 16 Healthy Subjects

A Phase 1 clinical trial for RAB001 (LLP2A-Ale) has been registered on ClinicalTrials.gov (NCT07545018) examining safety, tolerability, and pharmacokinetics in 16 healthy subjects across two dose groups (400 μg/kg and 750 μg/kg) for the treatment of Osteonecrosis of the Femoral Head. The single-center, randomized, double-blind, placebo-controlled dose escalation study includes both single-dose and multiple-dose phases with injections administered once every 2 weeks.

Observational Study Biomarkers Osteoarthritis China

ClinicalTrials.gov registered an observational study (NCT07544823) titled 'Screening for Biomarkers of Osteoarthritis' conducted in China, posted April 22, 2026. The study intends to collect blood samples from osteoarthritis patients and suspected patients at a tertiary hospital orthopedic outpatient department, using diagnostic and differential diagnostic tests to verify candidate biomarkers. Researchers aim to screen biomarkers with favorable validity and reliability to support early prevention, early diagnosis, and individualized intervention for osteoarthritis.

Combined Ovarian Tissue and Oocyte Cryopreservation for Fertility

NIH ClinicalTrials.gov registered observational study NCT07546123 will compare combined ovarian tissue cryopreservation with oocyte cryopreservation against oocyte cryopreservation alone in oncological patients undergoing gonadotoxic treatments. The study will collect data from two groups of patients assigned based on their planned gonadotoxic therapy and available time before treatment initiation. The primary endpoints are the number of oocytes retrieved per ovarian stimulation cycle and the oocyte retrieval rate between the two groups.

Phase 1 ISAR InflEx Trial: Exercise Inflammation CVD

A new Phase 1 clinical trial called ISAR InflEx (Inflammation and Exercise) has been registered on ClinicalTrials.gov under identifier NCT07543666, with an estimated start date of April 22, 2026. The trial will investigate how three distinct exercise modalities—moderate-intensity, vigorous-intensity, and short-duration maximal exercise—affect systemic inflammation and immune function in sedentary adults with obesity, a population at elevated risk for cardiovascular disease. The study aims to characterize exercise as a potential anti-inflammatory intervention for CVD prevention, enrolling participants who meet specific inclusion criteria related to sedentary behavior and weight status.

XR Resilience Training RCT for 232 Hospital Nurses

A new ClinicalTrials.gov registry entry (NCT07544498) describes a pragmatic randomized controlled trial evaluating an extended reality (XR) based resilience training program for approximately 232 hospital nurses across several European countries. The trial compares eight immersive XR training sessions delivered via head-mounted display over ten weeks against a waitlist control, measuring perceived stress as the primary outcome.

Protego Biopharma Heteroaryl Diamide IRE1/XBP1S Activator Patent EP4347568A1

The European Patent Office published patent application EP4347568A1 on 15 April 2026, filed by Protego Biopharma, Inc. and The Scripps Research Institute, covering heteroaryl diamide compounds as IRE1/XBP1S pathway activators. The application lists eight named inventors and spans multiple therapeutic classifications including metabolic, cardiovascular, musculoskeletal, and neurological disease indications. The patent is now publicly available and designates all EPC contracting states across the EU and beyond.

Macrocyclic Compounds for Treating Cancer (EP4151641A1)

European Patent Office published EP4151641A1 on April 15, 2026, covering macrocyclic compounds for treating cancer. The patent lists Turning Point Therapeutics, Inc. as applicant and eight named inventors, with IPC classifications spanning C07D 498/22, A61P 35/00, and A61K 31/5383. The patent designates all EU member states as covered jurisdictions, conferring exclusivity across the European market.

Novel Bridged Bicycloalkyl-Substituted Aminothiazoles and Their Methods of Use

Temple University of the Commonwealth System of Higher Education has been granted European Patent EP4219486A1 for novel bridged bicycloalkyl-substituted aminothiazole compounds and their methods of use, published April 15, 2026. The patent designates 31 European Patent Convention member states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands. Inventors include CHILDERS Wayne E., ABOU-GHARBIA Magid A., MORTON George C., ISSA Jean-Pierre J., and ZHANG Hanghang, with applications classified under A61K 31/426 (antineoplastic pharmaceutical preparations).

EPO Publishes MOF Linkers Patent Application by Universiteit Antwerpen

The EPO published patent application EP4326436A1 for MOF (Metal-Organic Framework) and MOF linkers and their manufacturing method, filed by Universiteit Antwerpen. The inventors are Christophe Vande Velde, Rosa Fucci, and Leili Esrafili-Dizaji. The application covers IPC classifications B01J 31/26 and C07D 333/40, relating to catalysts and heterocyclic compounds. The patent designates all standard European contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Kumquat Biosciences EP4203952A1 Heterocyclic Compounds Patent

Kumquat Biosciences Inc. has obtained European patent publication EP4203952A1 for heterocyclic compounds and uses thereof, covering compositions with potential therapeutic applications. The patent names five inventors — Liu Yi, Ren Pingda, Li Liansheng, Zhu Zhimin, and Zhu Xiuwen — and was published on April 15, 2026. The application is designated across 31 European states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands, among others.

EP4122537A1 - Bridged Tricyclic Carbamoylpyridone Compounds

Gilead Sciences, Inc. has received EPO Publication EP4122537A1 for bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use, published on 15 April 2026. The application covers heterocyclic compounds with potential therapeutic applications, classified under IPC codes including C07D 471/04, C07D 491/06, and A61K 31/4375. The designation extends to 34 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Triazine Compound Salt Crystal Form, Tanabe Pharma, EP4215244A1, Apr 15 2026

The European Patent Office published patent EP4215244A1 on April 15, 2026, covering triazine compound salt crystal forms and production methods. The patent is assigned to Tanabe Pharma Corporation with four named inventors: Yamagami, Setsuta, Sugiura, and Ueda. The patent is designated across 31 European states including DE, FR, GB, IT, NL, ES, and SE.

IRBM Azole SHP2 Inhibitors Patent EP4345101A1

The European Patent Office published patent application EP4345101A1, filed by IRBM S.P.A. and C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening, covering azole derivatives as SHP2 inhibitors for therapeutic use. The application includes claims for treating cancer, immune disorders, and respiratory conditions, with inventors including Alessia Petrochchi, Christian Montalbetti, Romano Di Fabio, Alina Ciammaichella, and Ilaria Rossetti. The publication is designated for all European member states.

Captor Therapeutics European Patent Application EP4347579A1 for MCL-1 Targeted Protein Degradation

Captor Therapeutics S.A. has obtained publication of European patent application EP4347579A1 covering bifunctional compounds designed to bind ubiquitin ligase and recruit the MCL-1 protein for degradation, with potential therapeutic application in oncology. The application was published on April 15, 2026 with claims spanning heterocyclic compound compositions under IPC classifications C07D 401/14, C07D 471/04, C07D 513/04, and related therapeutic uses under A61P 35/00 and A61K 31/4439. The designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

Roche EP4251614A1: N-Substituted Aniline Hepatitis B Treatment

The EPO has granted patent EP4251614A1 to F. Hoffmann-La Roche AG covering N-substituted 4-(5-phenyl-1,3,4-oxadiazol-2-yl)aniline compounds for the treatment and prophylaxis of hepatitis B virus infection. The patent, filed with four named inventors (LIN Xianfeng, YUN Hongying, ZHANG Bo, ZHENG Xiufang), carries IPC classifications spanning C07D chemical compounds and A61K/A61P pharmaceutical preparations. Designated states include all major European Patent Convention member states. This grant confers exclusive rights to Roche across EU member jurisdictions for the claimed HBV therapeutic applications.

EP4144736A1 - Azabenzimidazoles AMPA Receptor Modulators, Janssen, Apr 15, 2026

The EPO published patent application EP4144736A1 titled 'Azabenzimidazoles and Their Use as AMPA Receptor Modulators' on April 15, 2026, covering novel heterocyclic compounds as AMPA receptor modulators for neurological and pain conditions. The application was filed by Janssen Pharmaceutica NV with 13 named inventors. The patent designates 37 EPO contracting states.

Celgene/Zoetis Helminthic Drug Patent Published by EPO

The European Patent Office published patent application EP4232449A1 for Celgene Corporation and Zoetis LLC, covering heterocyclic compounds and their use for treating helminthic infections and diseases, published April 15, 2026. The compounds carry multiple IPC classifications including C07D 417/14, C07D 413/14, C07D 401/14, C07D 471/04, C07D 491/048, and are designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, SE. The publication establishes priority rights and enables public inspection of the specific heterocyclic compound compositions and therapeutic uses disclosed in the application.

ISO 14001 Updated to Drive Environmental Action

ISO has published ISO 14001:2026, an updated environmental management standard that shifts organizational focus from environmental reporting to active, risk-driven environmental management. The standard requires organizations to identify their most significant environmental aspects and concentrate resources where impacts and risks are greatest, rather than pursuing uniform actions. The new edition also strengthens alignment with other management system standards including ISO 9001 (quality), ISO 45001 (occupational health and safety), and ISO 50001 (energy management), allowing integrated implementation. Compliance and environmental management professionals should note that ISO 14001 is explicitly described as a governance framework supporting leadership in understanding environmental risk and aligning environmental performance with broader organizational objectives. The standard is positioned as applicable across diverse contexts from complex industrial sectors (oil and gas, chemical manufacturing, nuclear energy) to community organizations, emphasizing its flexibility in addressing varied organizational footprints.

UNDRR Chief: Critical Infrastructure Must Prioritize Resilience

The UNDRR Special Representative for Disaster Risk Reduction, Kamal Kishore, has published a thought leadership piece on ISO's website arguing that critical infrastructure resilience can no longer be optional. The article cites the Global Assessment Report on Disaster Risk Reduction 2025, noting that while direct disaster costs reach approximately USD 202 billion annually, the true cost is eleven times higher — nearly USD 2.3 trillion annually — when cascading and indirect impacts are included. The piece highlights ISO 22372, an international standard developed from the Principles for Resilient Infrastructure, as a practical pathway for achieving resilience and complements regulatory frameworks such as the EU's Resilience of Critical Entities (CER) Directive. Organizations responsible for critical infrastructure systems in energy, water, transport, and healthcare sectors should consider the standard as a benchmark for identifying hidden vulnerabilities and strengthening continuity of essential services under stress.

ISO 14001:2026 Published, Raising Environmental Performance Bar

ISO has published ISO 14001:2026, a revised edition of the world's most widely used environmental management standard, trusted by more than 670,000 certified organizations worldwide. The new edition introduces clearer guidance, stronger alignment with environmental priorities including climate change, biodiversity, and resource efficiency, and greater emphasis on leadership, governance, and integrated value-chain management. Organizations currently certified to ISO 14001 should monitor transition timelines from their certification bodies, while those not currently certified can consider adopting the revised standard.

Senate Rejects Iran War Powers Resolution 46-51

The Senate voted 46-51 on April 22, 2026 to reject the Motion to Discharge S.J.Res. 114, a joint resolution that would have directed the removal of United States Armed Forces from hostilities within or against Iran that have not been authorized by Congress. The measure required a simple majority to advance but fell short by five votes, with 51 senators voting no and three not voting. The resolution remains in committee and was not advanced to the full Senate for consideration.